[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3
|
[2] |
中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2022[M]. 北京: 人民卫生出版社, 2022.
|
|
Organized by the Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) breast cancer diagnosis and treatment guide-2022[M]. Beijing: People’s Health Publishing House, 2022.
|
[3] |
HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer[J]. N Engl J Med, 2022, 386(10): 942-950.
doi: 10.1056/NEJMoa2114663
|
[4] |
XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021, 27(11): 1904-1909.
doi: 10.1038/s41591-021-01562-9
pmid: 34737452
|
[5] |
ANDRÉ F, CIRUELOS E M, JURIC D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021, 32(2): 208-217.
doi: 10.1016/j.annonc.2020.11.011
|
[6] |
RUGO H S, LEREBOURS F, CIRUELOS E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study[J]. Lancet Oncol, 2021, 22(4): 489-498.
doi: 10.1016/S1470-2045(21)00034-6
|
[7] |
HOWELL S J, CASBARD A, CARUCCI M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial[J]. Lancet Oncol, 2022, 23(7): 851-864.
doi: 10.1016/S1470-2045(22)00284-4
pmid: 35671774
|
[8] |
冀辰辰, 李健斌, 江泽飞. HER2阳性乳腺癌分层治疗新策略[J]. 中国肿瘤临床, 2022, 499(22): 1147-1150.
|
|
JI C C, LI J B, JIANG Z F. New strategy for stratified treatment of HER2-positive breast cancer[J]. Chin J Clin Oncol, 2022, 499(22): 1147-1150.
|
[9] |
WANG T, CHEN J Y, YANG J, et al. CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis[J]. Transl Breast Cancer Res, 2022, 3: 22.
doi: 10.21037/tbcr
|
[10] |
YAN Y, LI Q, LI J B. Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates[J]. Transl Breast Cancer Res, 2022, 3: 18.
doi: 10.21037/tbcr
|
[11] |
HURVITZ S A, HEGG R, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117.
doi: 10.1016/S0140-6736(22)02420-5
|
[12] |
肖玉铃, 朱秀之, 江一舟, 等. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
doi: 10.19401/j.cnki.1007-3639.2022.08.001
|
|
XIAO Y L, ZHU X Z, JIANG Y Z, et al. New research advances and future prospect in precision treatment of triple-negative breast cancer[J]. China Oncol, 2022, 32(8): 669-679.
|
[13] |
JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5.
doi: 10.1016/j.ccell.2019.02.001
|
[14] |
龚畅, 林群, 宋尔卫. 肿瘤免疫治疗机制及乳腺癌免疫治疗进展[J]. 中华临床医师杂志(电子版), 2020, 14(11): 857-861.
doi: 10.3877/cma.j.issn.1674-0785.2020.11.001
|
|
GONG C, LIN Q, SONG E W. Mechanism of immunotherapy and progress in immunotherapy of breast cancer[J]. Chin J Clin Electron Ed, 2020, 14(11): 857-861.
|
[15] |
YANG L B, LIU Q, ZHANG X Q, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25[J]. Nature, 2020, 583(7814): 133-138.
doi: 10.1038/s41586-020-2394-6
|
[16] |
LIU J Q, WANG Y, TIAN Z L, et al. Multicenter phase Ⅱ trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer[J]. Nat Commun, 2022, 13(1): 3011.
doi: 10.1038/s41467-022-30569-0
|
[17] |
WANG B Y, SUN T, ZHAO Y N, et al. A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer[J]. Nat Commun, 2022, 13(1): 4025.
doi: 10.1038/s41467-022-31704-7
pmid: 35821019
|
[18] |
SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121.
doi: 10.1056/NEJMoa1809615
|
[19] |
MILES D, GLIGOROV J, ANDRÉ F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(8): 994-1004.
doi: 10.1016/j.annonc.2021.05.801
|
[20] |
CORTES J, RUGO H S, CESCON D W, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022, 387(3): 217-226.
doi: 10.1056/NEJMoa2202809
|
[21] |
BARDIA A, HURVITZ S A, TOLANEY S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541.
doi: 10.1056/NEJMoa2028485
|
[22] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690
|
[23] |
RUGO H S, BARDIA A, MARMÉ F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2022, 40(29): 3365-3376.
doi: 10.1200/JCO.22.01002
|